Cargando…

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales:	Martinez-Cibrian, Nuria, Ortiz-Maldonado, Valentín, Español-Rego, Marta, Benitez-Ribas, Daniel, Cid, Joan, Lozano, Miquel, Navarro, Sergio, Magnano, Laura, Gine, Eva, Saldarriaga, Juan Gonzalo Correa, Mozas, Pablo, Lobato, Luis Gerardo Rodríguez, Brillembourg, Helena, Montoro, Mercedes, Ayora, Pilar, Alserawan, Leticia, Martínez Roca, Alexandra, Lopez-Guillermo, Armando, Urbano Ispizua, Avaro, Juan, Manel, Pascal, Mariona, Delgado, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430432/ http://dx.doi.org/10.1097/01.HS9.0000972452.48383.99

Ejemplares similares

P1394: RITUXIMAB BASED LYMPHODEPLETION MAY INCREASE ENGRAFTMENT AND EFFICACY OF SECOND INFUSIONS OF CART19 CELLS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2023)

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2022)

P1364: PHARMACOKINETIC PROFILE OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A), FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T CELL THERAPY FOR PATIENTS WITH RELAPSED/ REFRACTORY B CELL MALIGNANCIES (IMAGINE STUDY)
por: Malhotra, Pankaj, et al.
Publicado: (2023)

P1409: PHASE-2 STUDY OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A) FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T WITH FRACTIONATED INFUSIONS FOR PATIENTS WITH RELAPSED REFRACTORY B CELL MALIGNANCIES: IMAGINE STUDY
por: Malhotra, Pankaj, et al.
Publicado: (2023)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
por: Ying, Zhitao, et al.
Publicado: (2020)

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT
por: Ahmed, Nausheen, et al.
Publicado: (2023)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)
por: Locke, F., et al.
Publicado: (2022)

Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2022)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

1391. Enhanced Education and Administration of Influenza Vaccine in a Pediatric Subspecialty Practice
por: McCarthy, Carol A, et al.
Publicado: (2020)

Plasma Metabolomic Profiling in 1391 Subjects with Overweight and Obesity from the SPHERE Study
por: Frigerio, Gianfranco, et al.
Publicado: (2021)

1391. Body Mass Index and Leptin Levels at Different Stages of the Tuberculosis Spectrum
por: Askar, Wajih, et al.
Publicado: (2021)

1391. "Going Viral for Good: The Global Impact of #IDTwitter in the Infectious Diseases Twitter Community"
por: Mehta, Priyal, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
por: Delgado, Julio, et al.
Publicado: (2019)

Mar cel Levi
por: Baltesen, Frits
Publicado: (2021)

S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY
por: Roddie, Claire, et al.
Publicado: (2023)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

1391. Latent Tuberculosis Screening Cascade in Liver Transplant Candidates: A Single, Transplant Center Experience
por: Medvedeva, Natalia, et al.
Publicado: (2019)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2021)

Pathogenic Carboxyl Ester Lipase (CEL) Variants Interact with the Normal CEL Protein in Pancreatic Cells
por: Dalva, Monica, et al.
Publicado: (2020)

P1399: INITIAL CLINICAL RESULTS OF EUPLAGIA-1, A PHASE 1/2 TRIAL OF POINT-OF-CARE MANUFACTURED GLPG5201 IN R/R CLL/SLL WITH OR WITHOUT RICHTER’S TRANSFORMATION
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2023)

T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
por: Battram, Anthony M., et al.
Publicado: (2022)

Report from LHC MDs 1391 and 1483: Tests of new methods for study of nonlinear errors in the LHC experimental insertions
por: Maclean, Ewen Hamish, et al.
Publicado: (2017)

1391. Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A Systematic Review and Meta-Analysis of Observational Studies
por: Aljefri, Doaa, et al.
Publicado: (2018)

Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia
Publicado: (2023)

Expression, Characterization and Synergistic Interactions of Myxobacter Sp. AL-1 Cel9 and Cel48 Glycosyl Hydrolases
por: Ramírez-Ramírez, Norma, et al.
Publicado: (2008)

Relationship between Addiction Relapse and Self-Efficacy Rates in Injection Drug Users Referred to Maintenance Therapy Center of Sari, 1391
por: Abdollahi, Zahra, et al.
Publicado: (2014)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
por: Wu, Liviawati S., et al.
Publicado: (2022)

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
por: Trias, Esteve, et al.
Publicado: (2022)

Cel i terra : l'art dels cartógrafs a la Universitat de Valéncia /
Publicado: (1996)

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
por: Maloney, David G., et al.
Publicado: (2021)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review
por: Rivero, Andrea, et al.
Publicado: (2023)

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
por: Bartoló-Ibars, Ariadna, et al.
Publicado: (2021)

Erratum: Halonen et al. “Associations between Nighttime Traffic Noise and Sleep: The Finnish Public Sector Study” [120:1391–1396 (2012)]
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5mg0k0a94n42ba7c9cer8ep1t9